| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 2002-05-02 |
| Identifiers | MRN HR-NI029-SYN; SSN (made up) 000-29-5108 |
| Document date | 2026-06-12 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
End of the eight-week intensive phase. [S]
Ms. Higuchi returns at the end of the intensive phase, having taken all 56 doses by video, the last pyrazinamide dose yesterday. The isolate was susceptible to isoniazid, rifampin, pyrazinamide and ethambutol, and ethambutol was stopped by phone three weeks ago when the result arrived. The two-week sputum showed no acid-fast bacilli, and its culture has had no growth. The cough has gone and the night sweats stopped a month ago. She has no nausea, yellowing, dark urine, abdominal pain, numbness, or change in vision. She is eating well and has gained 2.5 kg. She is writing two hours each morning and has sent a story to an editor. [S]
| Element | Detail |
|---|---|
| Treatment | 56 of 56 intensive-phase doses observed; ethambutol stopped three weeks ago |
| Susceptibility | Susceptible to all four first-line drugs |
| Symptoms | No cough or night sweats |
| Weight | 41.0 kg, up 2.5 kg |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough or sputum; not breathless |
| Constitutional | Negative | No fever or night sweats; energy better |
| Gastrointestinal | Negative | No nausea, abdominal pain or jaundice |
| Eyes | Negative | No change in vision or colors |
| Psychiatric | Negative | Mood better; PHQ-9 5 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 2026-04-17 to 2026-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 2026-04-17 to 2026-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-04-17 to 2026-10-15 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-12 | Body height | 148 | cm | S |
| 2026-06-12 | Body weight | 41 | kg | S |
| 2026-06-12 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 2026-06-12 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-06-12 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-06-12 | Heart rate | 80 | /min | S |
| 2026-06-12 | Respiratory rate | 16 | /min | S |
| 2026-06-12 | Body temperature | 36.8 | Cel | S |
| 2026-06-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 2026-06-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 10-35 U/L | Normal | S |
| 2026-06-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-12 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-12 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-12 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-06-12 | Visual acuity uncorrected Left eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 2026-06-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2026-06-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Looks well; weight 41.0 kg, BMI 18.7; temperature 36.8 °C, pulse 80 |
| Eyes | No icterus. Visual acuity 85 letters in each eye; Ishihara plates normal |
| Respiratory | Clear on both sides |
| Abdomen | Soft and non-tender |
| Neurological | Normal sensation in the feet |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | active | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No cough, fever or night sweats |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 41.0 kg, up 2.5 kg; albumin 3.8 g/dL; doses unchanged |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | No symptoms |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 26, AST 25 U/L, bilirubin 0.5 mg/dL, all normal |
| Laboratory | Monthly liver tests in the intensive phase (month one) | Monthly in the intensive phase because of low weight and albumin | Deferred | Missed: the liver tests due about four weeks into treatment were not drawn, because no visit was booked and the phone call that stopped ethambutol did not include a blood test. No harm judging by today's normal results and the absence of symptoms at every observed dose. Corrective action: blood tests due between visits are now booked as laboratory visits with a reminder to the observing nurse |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Deferred | Missed: the monthly vision check due about four weeks into treatment, while she was still taking ethambutol, was not done for the same reason. No harm: acuity 85 letters in each eye and normal color vision today, three weeks after ethambutol was stopped. Corrective action: any future ethambutol course is booked with monthly vision checks |
| Laboratory | Drug susceptibility testing of the first isolate | Once, on the first positive culture | Completed today | Susceptible to isoniazid, rifampin, pyrazinamide and ethambutol; ethambutol stopped three weeks ago |
| Laboratory | Two-month sputum smear and culture | At the end of the intensive phase | Completed today | Two-week specimen smear-negative with no growth so far; two-month induced specimen sent today |
| Laboratory | Blood count | At diagnosis, then as needed | Completed today | Hemoglobin 12.4 g/dL, up from 11.4 |
| Medication safety | Continuation-phase length | At the end of the intensive phase | Completed today | Four months planned, because there was no cavity; extension to seven months would be considered if the two-month culture were positive, because she is underweight |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | 56 of 56 doses observed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine continues |
| Medication safety | Rifampin drug-interaction review, including hormonal contraception | With every new medicine | Completed today | No new medicines |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Referred | Continuing with the public health center; results not part of her record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | PHQ-9 5, from 8; item 9 scored 0 |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025); WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022); Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children (2017); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Two-month culture result by phone. Preventive visit as booked. End-of-treatment visit after the 182nd dose. Call for cough, fever, weight loss, hepatitis symptoms or numbness. Next scheduled visit 2026-08-24: periodic adult preventive visit. [S]